Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Degree programmes
  • Modules
  • Jobs
  • People
  • Research Outputs
  • Academic units
  • Third Mission
  • Projects
  • Skills

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Degree programmes
  • Modules
  • Jobs
  • People
  • Research Outputs
  • Academic units
  • Third Mission
  • Projects
  • Skills
  1. Research Outputs

Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?

Academic Article
Publication Date:
2018
Short description:
Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus? / Santi, Daniele; Locaso, Michela; Granata, Antonio R; Trenti, Tommaso; Roli, Laura; Pacchioni, Chiara; Rochira, Vincenzo; Carani, Cesare; Simoni, Manuela. - In: PLOS ONE. - ISSN 1932-6203. - 13:6(2018), pp. 1-12. [10.1371/journal.pone.0199299]
abstract:
Introduction Appropriate algorithms for the prediction of cardiovascular risk are strongly suggested in clinical practice, although still controversial. In type 2 diabetes mellitus (T2DM), the benefi- cial effect of phosphodiesterase (PDE)-5 inhibitors is demonstrated on endothelial function but not on the estimation of cardiovascular risk. Aim To study whether the chronic Vardenafil administration to men with T2DM influences vari- ables correlated with the predicted long-term cardiovascular risk calculated by different vali- dated algorithms. Methods Per-protocol analysis of a longitudinal, prospective, randomized, placebo-controlled, dou- ble-blind, investigator-started, clinical trial. 54 male patients affected by T2DM were assigned to study (26patients) and control-group (28patients), respectively. The study included a treatment phase (24weeks) (Vardenafil/placebo 10mg twice-daily) and a follow- up phase (24weeks). Three time points were considered: baseline(V0), end of treatment (V1) and end of the study(V2). Parameters evaluated: endothelial health-related parameters and cardiovascular risk, assessed by calculating the Framingham (coronary hart disease [CHD], myocardial infarction [MI], stroke and cardiovascular disease [CVD]), ASSIGN and CUORE equations. Results Predicted cardiovascular risk at ten years resulted different using the three algorithms cho- sen, without differences between study and control groups and among visits. IL-6 was directly related to CHD, CVD and CUORE scores at V1 and with MI and STROKE at V2. Similarly, hs-CRP was directly related to CHD, MI, STROKE and CUORE only at V1 in the study group. Testosterone serum levels were inversely related to CHD and MI at V1 in study group. Discussion The predicted cardiovascular risk is different depending on the algorithm chosen. Despite no predictive risk reduction after six months of treatment, a possible effect of Vardenafil could be hypothesized through its action on inflammation markers reduction and through restoration of normal testosterone levels.
Iris type:
Articolo su rivista
Keywords:
Vardenafil, cardiovascular disease, type 2 diabetes mellitus, man
List of contributors:
Santi, Daniele; Locaso, Michela; Granata, Antonio R; Trenti, Tommaso; Roli, Laura; Pacchioni, Chiara; Rochira, Vincenzo; Carani, Cesare; Simoni, Manuela
Authors of the University:
ROCHIRA Vincenzo
SANTI Daniele
SIMONI Manuela
Handle:
https://iris.unimore.it/handle/11380/1163904
Full Text:
https://iris.unimore.it//retrieve/handle/11380/1163904/200435/082_Santi_et_al_PLOSone_2018.pdf
Published in:
PLOS ONE
Journal
  • Overview

Overview

URL

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199299
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.4.5.0